kabutan

Carna Biosciences, Inc.(4572) Summary

4572
TSE Growth
Carna Biosciences, Inc.
346
JPY
+6
(+1.76%)
Mar 16, 10:06 am JST
2.16
USD
Mar 15, 9:06 pm EDT
Result
PTS
outside of trading hours
347.8
Mar 16, 9:58 am JST
Summary Chart Historical News Financial Result
PER
PBR
21.5
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 16, 2026
Opening Mar 16, 9:00 am
337 JPY 2.11 USD
Previous Close Mar 13
340 JPY 2.13 USD
High Mar 16, 9:17 am
353 JPY 2.21 USD
Low Mar 16, 9:00 am
337 JPY 2.11 USD
Volume
86,700
Trading Value
0.03B JPY 0.19M USD
VWAP
348.0 JPY 2.18 USD
Minimum Trading Value
34,600 JPY 216 USD
Market Cap
6.64B JPY 0.04B USD
Number of Trades
147
Liquidity & Number of Trades
As of Mar 16, 2026
Liquidity
Slightly High
1-Year Average
452
1-Year High Dec 12, 2025
10,992
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 1,817,100
Feb 27, 2026 0 1,837,800
Feb 20, 2026 0 1,833,700
Feb 13, 2026 0 1,746,800
Feb 6, 2026 0 1,763,000
Company Profile
Carna Biosciences, Inc. specializes in drug discovery support services, primarily focusing on the production and sale of kinase proteins and analysis outsourcing. The company is also expanding into drug discovery.
Sector
Pharmaceuticals
Carna Biosciences, Inc. offers a diverse range of products and services supporting early-stage drug discovery, including the manufacture and sale of kinase proteins, assay development, profiling and screening services, and cell-based assay services. The company's strength lies in its extensive lineup of kinase proteins and assay kits. Additionally, Carna Biosciences is focusing on in-house drug discovery with kinase inhibitors, advancing research and development of new drugs in key disease areas such as cancer and immune-inflammatory disorders. For cancer-related projects, the company plans to conduct studies up to Phase II trials at most, while for other diseases, it aims to carry out Phase I trials or preclinical studies before out-licensing to pharmaceutical companies.